- DiaSorin’s dividend per share was €1.20, which exceeded the estimate of €1.12.
- The adjusted EBITDA came in at €394 million, slightly below the estimated €398 million.
- EBITDA was €387 million, under the estimate of €393.8 million.
- EBIT was reported at €258 million, slightly less than the estimate of €259.9 million.
- Adjusted net income was €236 million, surpassing the estimate of €222.8 million.
- Net income was €187 million, missing the estimate of €195.8 million.
- Revenue matched expectations at €1.19 billion.
- Stock analyst ratings include 7 buys, 9 holds, and 2 sells.
A look at DiaSorin SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead, DiaSorin SpA, a company manufacturing reagents for in vitro diagnostics, maintains an optimistic long-term outlook based on the Smartkarma Smart Scores analysis. The company received a promising score in Momentum, indicating a strong upward trend for its stock. Additionally, DiaSorin scored well in Growth and Resilience, reflecting potential for expansion and ability to withstand market fluctuations. While the Value and Dividend scores were not as high, the overall outlook for DiaSorin SpA appears positive, supported by its solid performance in key areas.
With a focus on manufacturing diagnostic reagents, DiaSorin SpA demonstrates potential for growth and resilience in the long term. The company’s strong Momentum score suggests positive performance indicators, while solid scores in Growth and Resilience further reinforce its position in the market. Although the Value and Dividend scores were average, DiaSorin SpA‘s overall outlook remains favorable, underpinned by its core business of providing essential products for in vitro diagnostics.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
